What You Should Know
- Microbiome intelligence and precision diagnostics platform Tiny Health announced the completion of an oversubscribed $33 million Series B financing round led by B Capital, bringing the company’s total cumulative funding to $46M.
- The financing syndicate included participation from existing investors—Spero Ventures, The Venture City, and Overwater Ventures—alongside new institutional backers including Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels, and Pari Passu Ventures.
- In tandem with the funding round, Tiny Health launched a $5M Microbiome Research Program designed to fund academic and clinical researchers investigating microbial intervention strategies across diverse health conditions.
Shotgun Metagenomics and Interventional RCT Evidence
Unlike legacy digital health testing kits that outsource analysis to commoditized third-party labs or rely on 16S sequencing, Tiny Health owns its entire in-house bioinformatics pipeline:
- Strain-Level Resolution: Uses shotgun metagenomic sequencing, detecting microbes across more than 120,000 reference genomes down to the strain level, while evaluating functional metabolic pathways, immune markers, and pathogenic colonization.
- Peer-Reviewed Interventional Trials: Tiny Health is the only direct-to-consumer/practitioner gut microbiome platform with an interventional randomized controlled trial (RCT) published in Pediatric Allergy and Immunology (2025), which demonstrated that its targeted biomarker-guided interventions reduced infants’ odds of developing eczema by 83%.
- Clinical Research Pipeline: Backed by four published scientific papers and an active second RCT, the company is expanding clinical investigations into inflammatory bowel disease (IBD), perimenopause/menopause, oncologic drug response, and GLP-1 receptor agonist metabolic interactions.
Accelerating “TinyAI” on 200,000 Longitudinal Profiles
Proceeds will support the scale of TinyAI, an analytical engine trained on Tiny Health’s proprietary repository of nearly 200,000 longitudinal gut and vaginal microbiome profiles:
- Closing the Longitudinal Gap: Initially built around early-life development—the critical “first 1,000 days” where infant immune programming is most malleable—the platform has expanded across the lifespan into healthy aging and longevity.
- Longevity Metrics: Features specialized adult biomarker tracking, including Gut Microbiome Age, Gut Resilience, and Gut-Body Connection scoring to track how microbial diversity correlates with systemic metabolic and inflammatory health.
- Adaptive Personalized Recommendations: TinyAI directly pairs deep metagenomic reads with actionable nutrition, lifestyle, and targeted biotherapeutic protocols, continuously updating clinical guidance as its multi-omic dataset expands.
Enterprise B2B Scaling via “Powered by Tiny”
While consumer-initiated kits established its initial brand, the company’s enterprise B2B infrastructure engine, Powered by Tiny, has become its fastest-growing segment:
- Commercial Momentum: The B2B business line grew 4x over the past year, with adult testing volume now surpassing pediatric volume.
- Practitioner Footprint: Integrated into the clinical workflows of more than 6,000 healthcare practitioners across independent functional/integrative clinics, academic health systems, longevity centers, and precision medicine practices.
- Enterprise Deployments: Powers remote microbiome diagnostics and interpretation for major health-tech and clinical partners, including Fullscript, Mayo Clinic’s Executive Health and Longevity Programs, Atria Institute, and Superpower.
- Academic Collaborations: Maintains active clinical research partnerships with institutions including Stanford Medicine, Mayo Clinic, and Massachusetts General Hospital.
Moving from Wellness Novelty to Clinical Infrastructure
Much like Everlywell’s enterprise pivot toward HEDIS gap closure, Tiny Health has mitigated high consumer acquisition costs by embedding its shotgun metagenomic platform directly into practitioner distribution (via Fullscript) and enterprise longevity clinics. As pharmaceutical development targets the gut-metabolic axis—particularly surrounding GLP-1 tolerability, gastrointestinal adverse effects, and immunotherapy responsiveness—longitudinal, strain-level metagenomic sequencing provides biopharma with the phenotypic biomarker data required to stratify patient response and optimize drug efficacy.
“We founded Tiny Health because the science is so impactful, the need is urgent, and no one else was building for the whole lifespan,” said Cheryl Sew Hoy, CEO and Founder of Tiny Health. “What started as a solution for my own family has become the infrastructure for an entire industry. This Series B round propels microbiome science as the foundational layer for the next frontier of medicine.”
